Soligenix Cultura de la Empresa

Dr. Richard C. Straube, M.D., MSc. has been the Chief Medical Officer and Senior Vice President of Soligenix, Inc. since January 2014. Dr. Straube leads Soligenix's clinical research with primary responsibility for the execution and completion of its multiple clinical programs, including its Phase 2 study in oral mucositis and its Phase 2/3 study in pediatric Crohn's disease. Dr. Straube served as the Chief Medical Officer at Stealth Peptides, Inc. Dr. Straube served as Chief Medical Officer of Critical Biologics Corporation since June 15, 2007. Dr. Straube served as Chief Scientific Officer and Executive Vice President of Research & Development of Ikaria, Inc. He served as Founding Chief Medical Officer for INO Therapeutics and was responsible for the clinical trials and subsequent approval of inhaled nitric oxide for the treatment of persistent pulmonary hypertension in the newborn. He served with Centocor, where Dr. Straube was responsible for the initial anti-cytokine and anti-endotoxin programs targeted at ameliorating inappropriate host responses to infectious and immunologic challenges. He has managed assessments of immunomodulation using monoclonal removal of inciting molecular triggers, removal of internal immune-messengers, augmentation of normal host defenses and maintenance of normal sub-cellular function in the face of injury. Dr. Straube is a board-certified pediatrician with clinical research experience in host-response modulation. He has a long and distinguished career of more than 35 years in both academia and industry, most notably with Centocor, Ohmeda Pharmaceuticals, INO Therapeutics and Stealth Peptides, Inc. Dr. Straube served as Director of Medical Affairs for T-Cell Sciences. He is a seasoned expert in the medical use of nitric oxide gas. He associated with INO Therapeutics. Dr. Straube has participated in designing and conducting a number of clinical trials, including the FDA-registration trials for inhaled nitric oxide. He is a co-author of a number of highly cited articles in the area of critical care therapies including inhaled nitric oxide therapy. While on the faculty at the UCSD Medical Center, his research focused on interventional studies for serious viral infections. He has residency training at the University of Chicago and completed a joint adult and pediatrician infectious diseases fellowship at the University of California, San Diego (UCSD), and as a Milbank Scholar completed training in clinical trial design at the London School of Hygiene and Tropical Medicine. Dr. Straube graduated from the University of Chicago with a B.A. in Biology and has a Medical Degree from the University of Chicago/Pritzker School of Medicine. Dr. Straube studied M.Sc. in Epidemiology from London School of Hygiene & Tropical Medicine.

Ms. Karen R. Krumeich has been Chief Financial Officer and Senior Vice President of Soligenix, Inc. since June 20, 2016 and serves as its Corporate Secretary. Ms. Krumeich has over 25 years of diverse experience in the financial and strategic management of emerging growth life science companies. She has a proven track record and expertise in corporate financial operations, equity financings and business development, including partnerships, mergers and acquisitions. Most recently, Ms. Krumeich served as a consultant providing finance, investor relations and business development services to Soligenix, Inc. and other healthcare companies. She worked as Vice President and Chief Financial Officer for several development-stage life science companies, including Cerecor, Inc. and Mela Sciences, Inc. where she was responsible for equity financings, corporate administrative functions and investor relations. She was a healthcare consultant Partner of Tatum LLC since July 2006. She served as Chief Financial Officer and Vice President for Finance at Strata Skin Sciences, Inc. (alternate name, Electro Optical Sciences Inc.) from January 2005 to April 24, 2006 and served as its Treasurer from May 2005 to May 4, 2006, Principal Accounting Officer until April 24, 2006 and Consultant since April 24, 2006. She was responsible for financial modeling and compliance programs as Director for Health Systems Management and Worldwide Franchise Management of Bristol-Myers Squibb. She served as an Interim Chief Financial Officer of Aksys Ltd. from September 19, 2006 to January 11, 2007. She served as Divisional Chief Financial Officer of the hospital group division of Henry Schein Inc. from September 2002 to July 2004, a publicly-held medical and dental products distributor. She served as Division Chief Financial Officer of Caligor, a distributor of medical products and served as Vice President for Finance of Anthra Pharmaceuticals, a developer of treatments for urological cancers and at GranCare Inc., a publicly held long-term care company. She served as a Financial Consultant with Consulting Associates from March 2000 to August 2002, a financial consulting firm. She served as Financial Consultant of Horn Murdock Cole from August 2004 to January 2005, a financial consulting firm. Ms. Krumeich began her career as a pharmacist and transitioned into finance after successfully completed the CPA exam. She received B.S. in Pharmacy from the University of Toledo College of Pharmacy and completed her post graduate work in accounting and finance at Cleveland State University.

Dr. Oreola Donini, Ph.D., has been the Chief Scientific Officer and Senior Vice President at Soligenix, Inc. since December 5, 2014. Dr. Donini served as Vice President of Preclinical Research and Development at Soligenix, Inc. since August 15, 2013 until December 4, 2014. Dr. Donini served as a Senior Director of Preclinical R&D at Inimex Pharmaceuticals Inc. Dr. Donini served as a Program Director at Kinetek Pharmaceuticals Inc. and managed a team which provided molecular modelling, bioinformatics and cheminformatics services. Dr. Donini has more than 13 years experience in drug discovery and preclinical development with start-up biotechnology companies and is instrumental in leading early stage development of several novel therapies into the clinic. She served as Vice President of Research and Development at ESSA Pharma Inc. Dr. Donini has received numerous graduate awards for her research on in silico design and computational chemistry. Dr. Donini received her Ph.D. from Queen's University in Kingston, Ontario and completed post-doctoral studies at the University of California San Francisco.

Adam Rumage serves as the Vice President, Project Management & Regulatory Affairs of Soligenix, Inc.. Adam started at Soligenix, Inc. in January of 2016. Adam currently resides in Greater New York City Area.

Ralph Cavalli serves as the Vice President Biopharmaceutical Development of Soligenix, Inc.. Ralph started at Soligenix, Inc. in March of 2017. Ralph currently resides in Greater Philadelphia Area.

Karen Krumeich serves as the SVP & Chief Financial Officer of Soligenix, Inc.. Karen started at Soligenix, Inc. in June of 2015. Karen currently resides in United States.